Climb Bio, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$67.9M | -$82.0M | -$40.3M | -$45.1M | -$35.7M |
| Operating expenses | $67.9M | $82.0M | $40.3M | $45.1M | $35.7M |
| Cash from operations | -$54.4M | -$15.6M | -$20.6M | -$37.4M | -$36.1M |
| Capital expenditure | $186,000 | $0 | $0 | — | — |
| Free cash flow | -$54.5M | -$15.6M | -$20.6M | — | — |
| Impairments | — | $0 | $180,000 | $0 | — |
| Total assets | $167.7M | $217.2M | $110.5M | $135.0M | $173.2M |
| Total liabilities | $7.3M | $5.3M | $2.9M | $6.3M | $6.0M |
Shares outstanding 57.3M · Free float 89.0%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.